Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effect of Artichoke Leaf Extract Supplementation on Lipid Profile of Chronic Kidney Disease Patients; a Double-Blind, Randomized Clinical Trial Publisher



Gatmiri SM1 ; Khadem E2 ; Fakhrian T3 ; Kamalinejad M4 ; Hosseini H5 ; Ghorat F6 ; Alamdari A1 ; Naderi N1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Nephrology Research Center, Center of Excellence in Nephrology, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Iran
  6. 6. School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

Source: Journal of Renal Injury Prevention Published:2019


Abstract

Introduction: Hyperlipidemia is considered a prominent risk factor for coronary heart disease. Coronary heart disease is the most common cause of mortality and morbidity in chronic kidney disease (CKD) patients. Objectives: The aim of this study was to evaluate the effects of artichoke leaf extract (ALE) supplementation on the lipid profile of CKD patients. Patients and Methods: A randomized, double-blind, placebo-controlled clinical trial was conducted in 38 CKD subjects (GFR<60 and > 15 mL/min/1.73 m2) with hypercholesterolemia (total cholesterol ≥ 200 mg/dL or low-density lipoprotein cholesterol [LDL-C] ≥ 110 mg/dL). The intervention group received an artichoke capsule (320 mg) and an indistinguishable placebo was given to the control group twice daily for 6 weeks. Lipid profile and appetite were assessed at week 8 and the results were compared with the baseline data. Results: ALE supplementation was correlated with a statistically significant decrease in mean total cholesterol (P = 0.028) and LDL-C (P = 0.005) compared to the control group. The two groups did not show a significant difference in high-density lipoprotein-cholesterol (P = 0.071) and triglyceride levels (P = 0.22). There was a statistically significant difference in appetite between the two groups (P = 0.016). Conclusion: This randomized controlled trial demonstrated that consumption of ALE supplement may improve appetite and lipid profile in CKD patients. © 2019 The Author(s).